JPMorgan Chase & Co. reaffirmed their neutral rating on shares of AstraZeneca plc (LON:AZN) in a research note released on Monday. The firm currently has a GBX 4,900 ($63.96) price objective on the biopharmaceutical company’s stock.
A number of other research firms also recently weighed in on AZN. Shore Capital reissued a hold rating on shares of AstraZeneca plc in a report on Thursday, June 23rd. Credit Suisse Group AG reissued an underperform rating and set a GBX 4,000 ($52.21) target price on shares of AstraZeneca plc in a report on Wednesday, July 13th. Citigroup Inc. reissued a buy rating on shares of AstraZeneca plc in a report on Friday, September 23rd. Goldman Sachs Group Inc. set a GBX 4,000 ($52.21) price target on AstraZeneca plc and gave the stock a sell rating in a research report on Wednesday, June 29th. Finally, Jefferies Group raised their price target on AstraZeneca plc from GBX 4,800 ($62.66) to GBX 5,050 ($65.92) and gave the stock a hold rating in a research report on Thursday, August 4th. Five equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of Hold and an average price target of GBX 4,937.91 ($64.46).
AstraZeneca plc (LON:AZN) opened at 5053.00 on Monday. The company’s 50-day moving average is GBX 5,006.61 and its 200 day moving average is GBX 4,427.08. The firm’s market cap is GBX 63.92 billion. AstraZeneca plc has a 12 month low of GBX 3,680.00 and a 12 month high of GBX 5,505.00.
The business also recently disclosed a dividend, which was paid on Monday, September 12th. Investors of record on Thursday, August 11th were paid a GBX 68.70 ($0.90) dividend. This represents a dividend yield of 1.37%. The ex-dividend date was Thursday, August 11th.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.